Loading
Palomino Laboratories Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Denbaars Steven, was filed 20 Apr 2026.
Palomino Laboratories Inc.: what insiders have been doing
Palomino Laboratories Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 22 October 2025 and 22 October 2026, 3 insiders published 4 filings.
Not one open-market sale was filed. On the buying side, 2 insiders reported 2 purchases totalling €85k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €42k from Denbaars Steven, disclosed on 20 April 2026. Among those who bought: 1 board member and 1 senior executive.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase dates back some time: it was published 187 days ago, on 20 April 2026.
With 4 filings in twelve months, the company is quieter than the median of 8 filings across the 277 companies we follow on the same exchange. Looking back to 2025, when coverage begins, insiders filed 2 purchases and no sales. The 10-K for the year ended 31 December 2025 shows -3.2 m USD of net income.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
8
Thresholds
n/a
Buy Volume
€84,858
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleRichard Ogawa1 buy
Steven Denbaars1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$14.00
Analyst consensus
Income statement
Net income-US$2.8M0.0% margin
Valuation
P/Book15.8x
Balance sheet & cash
Debt / Equity1%
Profitability & ownership
ROE-51.5%
ROA-27.2%
% insiders44.1%
% institutions0.0%
Last declaration on 4 August 2026
Declarations8 total
120,000 shares@ US$5.1492.7% of flowCommon StockSEC:0001493152-26-035982:0
12,500 shares@ US$4.00100.0% of flowCommon StockSEC:0001493152-26-018116:0
Canonical exit: 19 Jul 2026 (T+90)
12,500 shares@ US$4.007.3% of flowCommon StockSEC:0001493152-26-018119:0
Canonical exit: 19 Jul 2026 (T+90)
3,833,333 sharesCommon StockSEC:0001493152-25-019755:0
83,334 sharesCommon StockSEC:0001493152-25-017568:0
1,625,000 sharesCommon StockSEC:0001493152-25-017607:0
1,625,000 sharesCommon StockSEC:0001493152-25-017571:0
1,000,000 shares0Common StockSEC:0001213900-25-095630:0
8 of 8 declarations
About Palomino Laboratories Inc.
Palomino Laboratories Inc. is a company listed on the XNAS market, specializing in the development of pharmaceutical solutions. It focuses on innovation and research in the field of medical laboratories.
